Trial Profile
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Amgen
- 09 Jun 2014 New trial record
- 03 Jun 2014 Primary endpoint "infection rate"has been met.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.